

What is Claimed is:

1. A pharmaceutical formulation comprising salmeterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and budesonide or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
2. A pharmaceutical formulation according to claim 1 which is suitable for administration by inhalation.
3. A pharmaceutical formulation according to claim 1 wherein the pharmaceutically acceptable carrier or excipient is lactose.
4. A pharmaceutical formulation according to claim 1 wherein the pharmaceutically acceptable carrier or excipient comprises 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3- heptafluoropropane.
5. A method for the prophylaxis or treatment of a clinical condition in a mammal for which a selective β_2 -adrenoreceptor agonist and/or antiinflammatory corticosteroid is indicated, which comprises administering a therapeutically effective amount of a pharmaceutical formulation according to claim 1.
6. A method according to claim 6 wherein the clinical condition is a disease associated with reversible airways obstruction selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection, and upper respiratory tract disease.
7. A pharmaceutical formulation comprising salmeterol xinafoate and budesonide, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

8. A pharmaceutical formulation according to claim 7 which is suitable for administration by inhalation.

5 9. A pharmaceutical formulation according to claim 7 wherein the pharmaceutically acceptable carrier or excipient is lactose.

10 10. A pharmaceutical formulation according to claim 7 wherein the pharmaceutically acceptable carrier or excipient comprises 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3- heptafluoropropane.

15 11. A method for the prophylaxis or treatment of a clinical condition in a mammal for which a selective β_2 -adrenoreceptor agonist and/or antiinflammatory corticosteroid is indicated, which comprises administering a therapeutically effective amount of a pharmaceutical formulation according to claim 7.

20 12. A method according to claim 11 wherein the clinical condition is a disease associated with reversible airways obstruction selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection